b2venture St. Gallen, Switzerland
European early-stage venture firm backed by a community of angel investors and investing primarily at pre-seed and seed, with a later-stage direct-investment track.
Founded 2000
Type Venture capital 2 Fund V 2026-01-28 2026-01-28 €150M FinalclosehardcapEUR150m; narrative28Janvsmetadata30Jan; priorCHF150mtargetdistinct.
Second Digital Technologies Fund 2021-09-22 2021-09-22 $135M FinalUSD135mclose; b2ventureIVinSECAnaming; historicalvehicle.
SHOW MORE
$5M $300K – $11M Berlin, Germany $5M $300K – $11M Berlin, Germany $5M $300K – $11M Berlin, Germany $5M $300K – $11M Berlin, Germany $5M $300K – $11M Berlin, Germany $5M $300K – $11M Berlin, Germany $5M $300K – $11M Munich, Germany $5M $300K – $11M Switzerland $5M $300K – $11M Zurich · New York City · Berlin, Germany $5M $300K – $11M Zurich, Switzerland $25K $5K – $50K Switzerland $25K $5K – $50K Zurich, Switzerland $0 — – —
SHOW MORE
$14M 2022-03-30 Altoida M Ventures , Whitecap Venture Partners , HonorHealth , b2venture , ALPANA Ventures , Hikma Ventures , Fyrfly Venture Partners , Vi Partners $— 2026-06-17 Everlab b2venture , Plural €4M 2026-02-16 Sitegeist b2venture , Florian Schweitzer €4M 2026 Sitegeist b2venture $— 2026 Everlab b2venture , Plural $— 2025-12-10 Amplifold b2venture €2M 2025-09-11 Hive Robotics b2venture $4M 2025-07-03 Nautica Technologies b2venture , Jan-Hendrik Burk $— 2025-07-03 EDURINO b2venture $51M 2025-01-14 Nelly b2venture , Lakestar , Notion Capital $— 2024-12-20 1KOMMA5° b2venture $— 2024-12 1KOMMA5° b2venture $— 2024-11-28 Predium b2venture $— 2024-11-18 Quanta Dialysis Technologies b2venture €62M 2024-09-25 Marvel Fusion HV Capital , b2venture , Earlybird Venture Capital $— 2024-03-28 Aeovian Pharmaceuticals b2venture €6M 2024-02-07 DUDE CHEM b2venture , Frontline Ventures $— 2023-08-30 AI21 b2venture $— 2023-06-15 Nelly Lakestar , b2venture $6M 2023-03-28 Atlas Metrics b2venture , Founders Fund , another.vc , Redstone , Radius Capital , Cherry Ventures , TD Veen , Jan-Hendrik Burk , Filip Dames $— 2023-03-02 EDURINO b2venture $12M 2022-10-26 LatticeFlow Founders Fund , b2venture , Atlantic Bridge , FPV Ventures , OpenOcean , Andreas Goeldi $22M 2022-09-21 Ledgy Sequoia , Speedinvest , New Enterprise Associates , Visionaries , b2venture €590M 2022-06-23 Sumup Bain Capital Tech Opportunities , BlackRock , b2venture , Centerbridge Partners , Crestline Investors , Fin Capital , Sentinel Dome Partners $15M 2022-03-22 Decentriq b2venture , Eclipse , Kushagra Vaid $— 2022-03-04 Volocopter b2venture $— 2022 Skribble b2venture $40M 2021-11-19 Flytrex OurCrowd , b2venture , Blackhorn Ventures , Benhamou Global Ventures , BRM Group $— 2021-10-04 Fruitcore Robotics b2venture $10M 2021-09-06 Ledgy Sequoia , Visionaries , UI Path , Vi Partners , Front Ventures , Creathor Ventures , b2venture $— 2021-03-24 Blacklane b2venture $— 2021-03-17 Flytrex b2venture $— 2020-08-31 Semalytix b2venture , Fly Ventures $— 2020-07-14 Layer b2venture $— 2020-05-18 Regulus b2venture , Sierra Ventures $— 2020-01-13 Comtravo Creandum , M12 , Deutsche Bank , Project A , b2venture , Vendep Capital , Project A Ventures $23M 2019-11-05 Comtravo Simon Schmincke , Creandum , Deutsche Bank , Project A , b2venture , Vendep Capital , Project A Ventures $56M 2019-10-16 Healx Atomico , Amadeus Capital Partners , b2venture , Suranga Chandratillake , Irina Elena Haivas $— 2019-02-26 I2x b2venture $30M 2018-05-30 Ava Khosla Ventures , b2venture , DCM Ventures , Swisscom Ventures , TSVC $— 2016-04-15 Beekeeper b2venture $— Unknown date Vestigas b2venture $— Unknown date Miss Moneypenny Technologies GmbH b2venture $— Unknown date Kiin b2venture $— Unknown date Flyboard b2venture $— Unknown date Flyboard b2venture $— Unknown date Demoboost b2venture $— Unknown date Augmented Industries b2venture $— 2025-03-12 Vantis Health b2venture $— 2025 Nelly Solutions b2venture , Lakestar , Notion Capital $— 2022-03-28 Weaver b2venture $— 2022 Flitter b2venture $— 2021-09-23 Sternum b2venture $4M 2019-08-06 DeepCode b2venture , Earlybird Venture Capital , Peter Lasinger , Christian Nagel $— 2015-05-27 Campanda Accel , b2venture $— Unknown date Vantis b2venture $— Unknown date TextCortex b2venture $— Unknown date Finway b2venture $— Unknown date GTX Medical b2venture
SHOW MORE
team@apexlogos.ai · 1 hour ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size, status and stages
| Measure | Amount/status | Evidence and date | Interpretation |
|---|---|---|---|
| Fund V | **EUR 150m, final close at hard cap** | [Official announcement](https://www.b2venture.vc/stories/closing-fund-v-at-eu150m-hard-cap-to-support-the-next-generation-of-european-tech-leaders ), dated 2026-01-28; page also displays publication metadata 2026-01-30 | Latest-known individually identified fund found in searches through 2026-10-06. Approximately 35 early-stage European investments; industry-agnostic, defensible technologies. Named initial investments include Nautica, Hive Robotics, Augmented Industries and assemblean. A closed fund, not AUM. |
| Second Digital Technologies Fund (b2venture IV in SECA naming) | **USD 135m, final close** | [Fund counsel YPOG announcement](https://9177093.fs1.hubspotusercontent-eu1.net/hubfs/9177093/YPOG%20Press%20Release%20btov%20second%20DTF%20Fund.pdf ), 2021-09-22 | Historical fund; seed/Series A European strategy. Do not treat USD 135m as current uninvested capital. |
| Capital under management | **EUR 500m** | [SECA Yearbook 2025](https://www.seca.ch/media/y1jomuhq/seca-yearbook-2025.pdf ), 2025 edition | Historical aggregate, not an individual fund size or current verified 2026 AUM. |
Earlier Swiss VC reports listed a CHF 150m Fund V target; that fundraising-era currency/target is different from the final EUR 150m close. Use the later official final-close announcement for Fund V. [Swiss VC Report 2024](https://www.fonds-de-technologie.ch/fileadmin/user_upload/presse/2024/2024.01.01_VCReport_2024_web_1_.pdf ), 2024 edition. No newer named fund close was found; this is latest-known rather than a guarantee that none exists.
The firm's [portfolio FAQ](https://www.b2venture.vc/portfolio?9a4a0d23_page=20 ), undated and accessed 2026-10-06, explicitly states **seed and Series A**, tickets **EUR 250k–5m**, average **EUR 1m**. Verified pre-seed transactions below support adding pre-seed to demonstrated activity. The [founder biography](https://www.b2venture.vc/team/florian-schweitzer ), undated, distinguishes dedicated early funds from a direct track that also invests later. Historical Series B transactions do not make Fund V a growth fund. SECA's undated member listing uses a broader EUR 0.25m–10m range and includes expansion; the FAQ, directory and Signal figures should retain their different scopes rather than be merged into one firm check range.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Second Digital Technologies Fund | USD 135000000 | 2021-09-22 |
| Fund V | EUR 150000000 | 2026-01-28 | SHOW MORE
team@apexlogos.ai · 2 hours ago
Match research 2026-10-06 / B2venture / sha256:c61732f8a360bf4668bc84b486cf3cc468458ef6d13729c0c5ef6ce96cbac0f2 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
Additional verified portfolio leads, without independently reconstructed round attribution: the [current official portfolio](https://b2venture.vc/portfolio ), undated, lists **PAVE Space** since 2026 (orbital transfer vehicles) and **Amplifold** since 2025 (DNA origami-based rapid diagnostics). These are plausible strong deep-tech examples; exact rounds/vehicles require follow-up. General marketplaces, payments, administrative health software and ordinary SaaS in the saved record are not automatically classified as deep tech.
## Named neurotech investments and boundaries
**GTX Medical / ONWARD Medical — direct neurotechnology, high-confidence firm-family attribution.** The firm's [official paginated portfolio](https://www.b2venture.vc/portfolio?9a4a0d23_page=17&aa668c5b_page=18 ), undated, lists ONWARD since **2016**, developing therapies to restore movement after spinal cord injury. The [company's 2021 IPO prospectus](https://live.euronext.com/sites/default/files/2021-10/Prospectus%20-%20Onward%20Medical%20NV.pdf ), October 2021, confirms former GTX Medical naming and implantable/non-invasive spinal cord neurostimulation. This qualifies directly because the devices stimulate neural circuits. [Forbes reporting](https://www.forbes.com/sites/matthewherper/2018/11/01/swiss-startup-aims-to-help-paralyzed-people-walk/ ), **2018-11-01**, attributes **USD 40.3m financing in August 2016** to investors including btov, Gimv and INKEF, citing PitchBook. The specific round stage, btov vehicle and contribution were not independently established; treat that amount as secondary and retain the corporate/Swiss-subsidiary identity caveat when reconciling GTX names.
**Altoida — brain-health diagnostics, confirmed historical participation; no neural interface established.** [VI Partners' official funding announcement](https://www.vipartners.ch/news/altoida-upsizes-its-series-a-round-to-20.3m-to-advance-its-first-in-class-ai-powered-neurocognitive-assessment-platform ), **2022-03-30**, names **BTOV as a new investor** in an additional **USD 14m Series A tranche**, taking the full Series A to **USD 20.3m**; M Ventures and Whitecap co-led. Altoida uses AI, AR tasks and digital biomarkers for cognition/neurological diagnostics. This is neurocognitive assessment, not EEG, implant stimulation or a BCI. Exact btov vehicle remains undisclosed; company claims about clinical validation require separate medical/regulatory review.
Saved leads **Aeovian Pharmaceuticals** and **Healx** should remain neuroscience/therapeutics or AI drug-discovery adjacency unless direct neural-device evidence emerges. **Neura Robotics** is robotics/embodied AI; its name alone does not make it neurotech. This research does not establish a dedicated current neurotech mandate, current willingness to fund a specific brain-interface company, or an exhaustive historical neurotech portfolio.
## Conflicts, gaps and concrete later-review notes
1. Review Sitegeist's saved `isLead: false` and USD 5m total: the investee calls b2venture a co-lead and reports EUR 4m. A converted or rounded Signal USD figure is not the original financing currency. Consolidate duplicate 2026 records only after round matching.
2. Review Nautica's saved non-lead classification against the firm's explicit lead claim. Keep USD 4m original seed amount separate from EUR conversions.
3. Hive's saved date is missing; official narrative supplies 2025-09-11 and lead status. Do not mistake site's later publication metadata for round date.
4. Altoida's USD 20.3m is the aggregate Series A after an additional USD 14m; avoid treating both as separate new financings. BTOV participation is firm-level, with no individual partner investment inference.
5. Match GTX Medical with ONWARD's corporate history carefully; preserve the 2016 historical claim, subsidiary distinctions and unsupported-stage caveat. Current portfolio listing alone does not prove continued ownership after IPO.
6. Preserve btov predecessor attribution but check whether legacy Industrial Technologies holdings now belong to a separate manager before importing additional legacy investments. This file does not transfer every historic btov investment to the current Fund V.
7. Use EUR 150m final Fund V close, dated January 2026, distinctly from historical AUM and CHF target reports. Current 2026 AUM, remaining deployment capacity, partner-specific check preferences and individual company allocations are unverified.
8. The snapshot's repeated Florian role and dated team titles should be reviewed against the current official team independently. No wholesale role cleanup is proposed from Signal.
9. Official story pages repeatedly show an event date and a different later publication date. Both are recorded where material; dates in investment tables use narrative event dates. Limited TechCrunch excerpt access and failed Signal firm access are disclosed above. Portfolio verification is substantive but not exhaustive across all saved transactions.
All linked web sources were accessed **2026-10-06**; undated pages are explicitly labeled. This is a self-contained research artifact, with no database or MCP Patch operations authorized or performed. SHOW MORE
team@apexlogos.ai · 2 hours ago
Match research 2026-10-06 / B2venture / sha256:c61732f8a360bf4668bc84b486cf3cc468458ef6d13729c0c5ef6ce96cbac0f2 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# b2venture
- Exact Adex ID: `B2venture`
- Canonical Adex URL: https://adex.page/firms/B2venture
- Official website: https://www.b2venture.vc/
- Research date and source access date: 2026-10-06
- Status: complete research for later review; no Adex/database updates performed.
## Summary and identity
b2venture is a European venture firm founded in 2000 in St. Gallen, Switzerland, combining early-stage funds with an angel-supported direct-investment track. Its predecessor branding was btov Partners; founding partner Florian Schweitzer described the rebrand on 20 March 2023. Historical btov transactions can therefore be relevant, but the investment vehicle and fund-team versus direct-track attribution still need care. Sources: [founder rebrand account, 2023-03-20](https://medium.com/brains-to-ventures/from-the-year-2000-to-b2venture-5359443ffe8e ), [official founder biography, undated](https://www.b2venture.vc/team/florian-schweitzer ), [SECA member listing, undated](https://www.seca.ch/en/find-members/b2venture-formerly-btov-partners/ ).
There is verified deep-tech exposure in fusion, autonomous robotics, and research-based AI tooling, plus direct neurotechnology exposure through GTX Medical/ONWARD Medical. Altoida provides a distinct brain-health diagnostic example rather than a neural interface. These examples do not establish a dedicated neurotech fund or an exclusive deep-tech mandate.
## Starting Adex and NFX Signal evidence
The saved exact-ID MCP Search snapshot `_sources/B2venture.adex.json`, retrieved 2026-10-06 at 19:29:44 UTC, identifies b2venture as a European firm investing primarily at pre-seed/seed with a later-stage direct track. It has null firm check-size fields, 14 role entries (including two Florian Schweitzer roles), and historical investment records including Sitegeist, Nautica Technologies, Marvel Fusion, LatticeFlow, Altoida, GTX Medical, Aeovian Pharmaceuticals, Healx, and many software/service businesses. The snapshot sources were principally collected on 2026-09-14. Those records are leads, not independently verified evidence or a definitive current team list.
The baseline NFX URL [Signal firm profile](https://signal.nfx.com/firms/b2venture ) returned an internal error on direct browsing. The baseline also cites [DeepTech Pre-Seed investor list](https://signal.nfx.com/investor-lists/top-deeptech-pre-seed-investors ); inclusion alone is not a firm mandate.
[Florian Schweitzer's Signal profile](https://signal.nfx.com/investors/florian-schweitzer ) was directly read on 2026-10-06. It identifies him as a b2venture partner, reports a USD 300k–11m range and USD 5.7m sweet spot, and includes DeepTech rankings from pre-seed through Series B. Its history lists Sitegeist (February 2026, USD 5m), assemblean, Orus Energy and other companies. These are personal-profile claims, not verified firm-wide check policy. The Sitegeist amount conflicts with the investee's EUR 4m announcement below.
## Fund size, status and stages
| Measure | Amount/status | Evidence and date | Interpretation |
|---|---|---|---|
| Fund V | **EUR 150m, final close at hard cap** | [Official announcement](https://www.b2venture.vc/stories/closing-fund-v-at-eu150m-hard-cap-to-support-the-next-generation-of-european-tech-leaders ), dated 2026-01-28; page also displays publication metadata 2026-01-30 | Latest-known individually identified fund found in searches through 2026-10-06. Approximately 35 early-stage European investments; industry-agnostic, defensible technologies. Named initial investments include Nautica, Hive Robotics, Augmented Industries and assemblean. A closed fund, not AUM. |
| Second Digital Technologies Fund (b2venture IV in SECA naming) | **USD 135m, final close** | [Fund counsel YPOG announcement](https://9177093.fs1.hubspotusercontent-eu1.net/hubfs/9177093/YPOG%20Press%20Release%20btov%20second%20DTF%20Fund.pdf ), 2021-09-22 | Historical fund; seed/Series A European strategy. Do not treat USD 135m as current uninvested capital. |
| Capital under management | **EUR 500m** | [SECA Yearbook 2025](https://www.seca.ch/media/y1jomuhq/seca-yearbook-2025.pdf ), 2025 edition | Historical aggregate, not an individual fund size or current verified 2026 AUM. |
Earlier Swiss VC reports listed a CHF 150m Fund V target; that fundraising-era currency/target is different from the final EUR 150m close. Use the later official final-close announcement for Fund V. [Swiss VC Report 2024](https://www.fonds-de-technologie.ch/fileadmin/user_upload/presse/2024/2024.01.01_VCReport_2024_web_1_.pdf ), 2024 edition. No newer named fund close was found; this is latest-known rather than a guarantee that none exists.
The firm's [portfolio FAQ](https://www.b2venture.vc/portfolio?9a4a0d23_page=20 ), undated and accessed 2026-10-06, explicitly states **seed and Series A**, tickets **EUR 250k–5m**, average **EUR 1m**. Verified pre-seed transactions below support adding pre-seed to demonstrated activity. The [founder biography](https://www.b2venture.vc/team/florian-schweitzer ), undated, distinguishes dedicated early funds from a direct track that also invests later. Historical Series B transactions do not make Fund V a growth fund. SECA's undated member listing uses a broader EUR 0.25m–10m range and includes expansion; the FAQ, directory and Signal figures should retain their different scopes rather than be merged into one firm check range.
## Named previous deep-tech investments
Round amounts below are total financing, not b2venture's individual commitment. Specific vehicles are generally undisclosed in these announcements.
| Company | Technology rationale | Verified attribution and financing | Sources/dates |
|---|---|---|---|
| **Sitegeist** | Autonomous modular construction robots using perception and adaptive control for concrete renovation in unstructured environments; substantial hardware/control engineering. | Investee names **b2venture and OpenOcean as lead investors** in **EUR 4m pre-seed**. | [Official investee funding release](https://sitegeist-robotics.com/sitegeist-raises-e4m-pre-seed-funding-to-bring-automated-ai-enabled-modular-robots-on/ ), **2026-02-16**. |
| **Hive Robotics** | Secure real-time swarm control, communication, embedded systems and sensor fusion for autonomous air, ground and maritime systems; technical autonomy infrastructure rather than ordinary SaaS. | Firm explicitly says it **led EUR 2m pre-seed**. | [Official investment rationale](https://www.b2venture.vc/stories/building-the-future-of-collaborative-robotics---why-we-invested-in-hive-robotics ), **2025-09-11**; page metadata also shows 2026-05-18. |
| **Nautica Technologies** | Autonomous underwater swarm robots that clean/inspect ship hulls and gather physical vessel data. | Firm explicitly says it **led the round**; its official social announcement describes **USD 4m seed**. | [Official rationale](https://www.b2venture.vc/stories/autonomous-robots-beneath-the-waves---why-we-invested-in-nautica-technologies ), **2025-07-03**; metadata also shows 2026-05-18. [Firm funding post](https://www.linkedin.com/posts/b2venture_big-congratulations-to-c%C3%A9dric-portmann-mina-activity-7346437002889678849-TwIk ), undated rendered post, accessed 2026-10-06. |
| **Marvel Fusion** | High-power short-pulse laser fusion with nanostructured fuel targets; energy physics and advanced laser engineering. | b2venture explicitly confirms contribution to **EUR 62.8m Series B**, led by HV Capital. | [Official funding story](https://www.b2venture.vc/stories/marvel-fusion-raises-more-than-eu60-million-seriess-b ), **2024-09-26**, metadata also 2026-01-22. |
| **LatticeFlow** | ETH-linked research-based tooling that detects/fixes computer-vision data and model failures; deep-tech classification rests on underlying ML research, not SaaS delivery alone. | Firm identifies it as a portfolio company at **USD 12m Series A**; independent reporting confirms existing btov participation. | [Official story](https://www.b2venture.vc/stories/latticeflow-secures-12-million-to-eliminate-ai-data-and-model-blind-spots-in-computer-vision ), **2022-10-26**, metadata also 2023-11-22. [TechCrunch](https://techcrunch.com/2022/10/26/latticeflow-raises-12m-to-eliminate-computer-vision-blind-spots/ ), **2022-10-26** (limited search excerpt). | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
Lakestar
Nelly$51M · 2025-01-14
Marvel Fusion€62M · 2024-09-25
Founders Fund
Atlas Metrics$6M · 2023-03-28
LatticeFlow$12M · 2022-10-26
Nautica Technologies$4M · 2025-07-03
Notion Capital
ALPANA Ventures
Altoida$14M · 2022-03-30
Amadeus Capital Partners
Healx$56M · 2019-10-16
Sumup€590M · 2022-06-23
Flytrex$40M · 2021-11-19
Cherry Ventures
Christian Nagel
Ledgy$10M · 2021-09-06
Ava$30M · 2018-05-30
Filip Dames
Sitegeist€4M · 2026-02-16
Fly Ventures
Semalytix$— · 2020-08-31
Frontline Ventures
DUDE CHEM€6M · 2024-02-07
Fyrfly Venture Partners
Hikma Ventures
HonorHealth
HV Capital
Irina Elena Haivas
Khosla Ventures
Kushagra Vaid
Decentriq$15M · 2022-03-22
M Ventures
Peter Lasinger
Sierra Ventures
Regulus$— · 2020-05-18
Simon Schmincke
Comtravo$23M · 2019-11-05
Speedinvest
Suranga Chandratillake
Whitecap Venture Partners
